The current study investigated the anti-proliferative, anti-motile and anti-invasive activities of an antagonist against CCR2, CAS 445479-97-0, by blocking the CCL2/CCR2 axis interaction and downregulating MMP-9 protein expression in human lung adenocarcinoma A549 cells in vitro. Here, CCR2 is linked to lung adenocarcinoma.